Why did the CSL share price smash the ASX 200 in April?

April has been kind to this healthcare giant's shares.

| More on:
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Unless something untoward happens later this session, the CSL Limited (ASX: CSL) share price will record a strong monthly gain in April.

As things stand, the biotherapeutics company's shares have risen a sizeable 5% since the turn of the month.

This compares favourably to the performance of the S&P/ASX 200 Index (ASX: XJO), which has recorded a respectable gain of 1.7% month to date.

Why is the CSL share price smashing the ASX 200?

While there hasn't been any real news out of the company to boost the CSL share price in April, there was a European investor site tour at the end of March that went down well with analysts.

For example, early in April, analysts at Morgan Stanley responded to the tour by reiterating their overweight rating and $339.00 price target on the company's shares. This suggests that there could still be plenty of room for them to climb higher despite April's heroics.

Goldman Sachs was also at the event and was pleased with what it heard. It commented:

Across site tours, presentations and various conversations throughout Marburg (Germany) and Bern (Switzerland), our key conclusion was that, having conducted an extensive program of expansion/improvement across fractionation and R&D efforts, CSL is now well positioned for a medium-term period of less capital-intensive growth (supporting our views that the current ROIC trough should markedly improve from here).

What else boosted its shares?

Also likely to be giving the CSL share price a lift in April was increased demand for defensive stocks after global recession fears grew.

Given that the healthcare sector is seen as defensive, investors appear to have been piling into some of the top stocks from this side of the market. This has led to the S&P/ASX 200 Health Care index recording a market-beating gain of 4% month to date.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »